Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ITK
REST API REST API
Homo sapiens
ITK is differentially expressed in 196 experiments: 68 organism parts: thymus, lung, ... (66 more);, 206 disease states: normal, acute lymphoblastic leukemia, ... (204 more);, 92 cell types 149 cell lines 23 compound treatments and 66 other conditions.
Synonyms PSCTK2, LYK, EMT
Orthologs ITK (Gallus gallus)   Itk (Mus musculus)   Itk (Rattus norvegicus)   itk (Danio rerio)   A7Z039_BOVIN (Bos taurus)   ITK (Xenopus laevis)   ITK (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, metal ion binding, protein tyrosine kinase activity, ATP binding, activation of phospholipase C activity, nucleotide binding, protein serine/threonine kinase activity, cellular defense response, non-membrane spanning protein tyrosine kinase activity, signal transduction, protein kinase activity, T cell receptor signaling pathway, T cell activation, adaptive immune response, cytokine production, interferon-gamma production, protein phosphorylation, intracellular signal transduction, NK T cell differentiation, interleukin-4 production
InterPro Term SH2, SH3_domain, Znf_Btk_motif, Prot_kinase_cat_dom, Pleckstrin_homology, SH3_2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene-Disease Assocation LYMPHOPROLIFERATIVE SYNDROME, EBV-ASSOCIATED, AUTOSOMAL, 1
UniProt Accession Q08881, Q7Z318, E5RFR5, E5RJY4
Search EB-eye ENSG00000113263
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-1880, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, ... (21 experiments)

Factor Value U/D Experiments
Jurkat
2
E-GEOD-1880, E-MTAB-62
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
MOLT4
2
E-MTAB-37, E-MTAB-62
HL-60
1
2
E-GEOD-24147, E-GEOD-96, E-MTAB-37
CHP212
1
E-MTAB-37
143 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, ... (36 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-AFMX-5, E-TABM-145, E-GEOD-6740, E-MTAB-25
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-22529, E-GEOD-2466, E-GEOD-1577, E-GEOD-2549, ... (45 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
colon carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
1
2
E-MTAB-62, E-GEOD-4290, E-MEXP-567
acute promyelocytic leukemia
1
2
E-GEOD-995, E-MTAB-62, E-GEOD-96
acute lymphoblastic leukemia
1
2
E-GEOD-96, E-MTAB-37, E-MTAB-62
200 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-7400, E-GEOD-3284, E-GEOD-5542, E-GEOD-412, ... (12 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
control
1
E-GEOD-3284
lipopolysaccharide
1
E-GEOD-3720
BCR/FGFR1
1
E-GEOD-15811
interferon-gamma
1
E-GEOD-5542
endotoxin
1
E-GEOD-3026
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-GEOD-22278, E-GEOD-837, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-974, E-GEOD-2466, ... (30 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.422 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM